Arthritis medication could prove effective in treating depression in older adults

A promising medical discovery could bring hope to seniors struggling with depression that is resistant to conventional treatments. A drug currently used for rheumatoid arthritis, tocilizumab, is showing efficacy in alleviating severe depressive symptoms.

Encouraging preliminary study

Researchers at the University of Bristol led a study involving 30 people with moderate to severe depression, with the results published in the prestigious journal JAMA Psychiatry. Participants were divided into two equal groups: the first group received tocilizumab, whilst the second received a placebo.

The preliminary results are encouraging for elderly patients who do not respond to traditional antidepressants. Individuals treated with tocilizumab showed significant improvements in depressive symptoms, anxiety and fatigue, accompanied by a notable increase in quality of life.

A revolutionary approach

This discovery is particularly significant because it represents a paradigm shift in the treatment of depression. Currently, antidepressant medications focus exclusively on regulating brain chemicals such as serotonin, norepinephrine and dopamine.

Dr Golam Khandakar, the study's lead author, believes this research marks a crucial milestone in the development of new therapies for depression, particularly for treatment-resistant forms. An immunotherapy-based approach could open new therapeutic avenues for seniors who do not benefit from current treatments.

Personalised care for the future

Dr Eimear Foley, co-author of the study, emphasises that this research brings us closer to more personalised care for depression. Future treatments could be selected to better match the biological profile of each individual patient, making it possible to offer the optimal treatment at the right time.

The next crucial step involves organising a large-scale Phase III clinical trial to confirm the efficacy of this innovative treatment and ultimately enable immunotherapy to be introduced into the therapeutic arsenal for depression.